Skip links

Combines Extensive Contact Lens & Pharma Experience

Facebook-square Twitter Instagram
Contact Us
scroll
Freya Ophthalmics

References

  • Quigley, H. A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80, 389–393 (1996).
  • Resnikoff, S. et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82, 844–851 (2004).
  • NEI. Report of the Glaucoma Panel. (1998).
  •  Asrani, S. et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma 9, 134–142 (2000).
  •  Kholdebarin, R. et al. Multicenter study of compliance and drop administration in glaucoma. Can. J. Ophthalmol. 43, 454–461 (2008).
  • MacKean, J. M. & Elkington, A. R. Compliance with treatment of patients with chronic open-angle glaucoma. Br. J. Ophthalmol. 67, 46–49 (1983).
  •  Stone, J. L., Robin, A. L., Novack, G. D., Covert, D. W. & Cagle, G. D. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch. Ophthalmol. 127, 732–736 (2009).
  •  Brown, M. M., Brown, G. C. & Spaeth, G. L. Improper topical self-administration of ocular medication among patients with glaucoma. Can. J. Ophthalmol. 19, 2–5 (1984).
  •  Winifield, A., Jessiman, D., Williams, A. & Esakowitz, L. A study of the causes of noncompliance by patients prescribed eyedrops. Can J Opthalmol 74, 477–480 (1984).
  •  Kass, M. A., Hodapp, E., Gordon, M., Kolker, A. E. & Goldberg, I. Patient administration of eyedrops: observation. Part II. Ann. Ophthalmol. 14, 889–893 (1982).
  •  Friedman, D. S., Nordstrom, B., Mozaffari, E. & Quigley, H. A. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology 112, 1500–1504 (2005).
  •  Bron, A., Hermann, M. & Creuzot-Garcher, C Diestelhorst, M. Monitoring individual compliance in glaucoma patients used to topical therapy. in Program and abstracts of the Association for Research in Vision and Ophthalmology 2007 Annual Meeting (2007).
  •  Hennessy, A. L., Katz, J., Covert, D., Protzko, C. & Robin, A. L. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology 117, 2345–2352 (2010).
  •  Ashburn, F. S., Goldberg, I. & Kass, M. A. Compliance with ocular therapy. Surv. Ophthalmol. 24, 237–248 (1980).
  •  Nordstrom, B. L., Friedman, D. S., Mozaffari, E., Quigley, H. A. & Walker, A. M. Persistence and adherence with topical glaucoma therapy. Am. J. Ophthalmol. 140, 598–606 (2005).
  •  Schwartz, G. F., Platt, R., Reardon, G. & Mychaskiw, M. A. Accounting for Restart Rates in Evaluating Persistence with Ocular Hypotensives. Ophthalmology 114, 648–652 (2007).
  •  Tsai, J. C., McClure, C. A., Ramos, S. E., Schlundt, D. G. & Pichert, J. W. Compliance barriers in glaucoma: A systematic classification. J. Glaucoma 12, 393–398 (2003).
  •  Zimmerman, T. J. & Zalta, A. H. Facilitating patient compliance in glaucoma therapy. Surv. Ophthalmol. 28, 252–258 (1983).
  •  Institute, N. N. E. Eye Health Data and Statistics. (2019).
  •  Lowe, P. Priorities for Presbyopes: Maintain Comfort and Continuity. in Review of Optometry (2016).
  •  Gromacki, S. Satisfying Boomers and Boomlets with Lenses. Contact Lens Spectr. (2008).
  • Brujic, S. & Miller, J. How Old Is Too Old for Contact Lenses? Rev. Cornea Contact Lens (2010).
  • Taniguchi, E. V, Kalout, P., Pasquale, L. R., Kohane, D. S. & Ciolino, J. B. Clinicians’ perspectives on the use of drug-eluting contact lenses for the treatment of glaucoma. Ther. Deliv. 5, 1077–1083 (2014).
  • Gasset, A. R., Ishii, Y., Kaufman, H. E. & Miller, T. Cytotoxicity of ophthalmic preservatives. Am. J. Ophthalmol. 78, 98–105 (1974).
  •  Berdy, G. J., Abelson, M. B., Smith, L. M. & George, M. A. Preservative-Free Artificial Tear Preparations: Assessment of Corneal Epithelial Toxic Effects. Arch. Ophthalmol. 110, 528–532 (1992).
  •  Stewart, W. C., Stewart, J. A. & Nelson, L. A. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr. Eye Res. 36, 391–398 (2011).
  •  Baudouin, C. et al. Diagnosing the severity of dry eye: A clear and practical algorithm. Br. J. Ophthalmol. 98, 1168–1176 (2014).
  •  Åkerblom, T., Aurell, E., Cristianansson, J., Kriisa-Kunnos, V. & Wiebert, O. A Multicentre Study Of The Effect And Tolerance Of Ocusert‐P‐40. Acta Ophthalmol. 58, 617–623 (1980).
  •  Saettone, M. F. & Salminen, L. Ocular inserts for topical delivery. Adv. Drug Deliv. Rev. 16, 95–106 (1995).
  •  W, L. OCUSERT – summary of panel discussion. (1975).
  •  Gangopadhyay, N., Daniell, M., Weih, L. A. & Taylor, H. R. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br. J. Ophthalmol. 84, 378–384 (2000).
  •  Daniell, M., Mills, R. & Morlet, N. Microbial keratitis: what’s the preferred initial therapy? Br. J. Ophthalmol. 87, 1167 (2003).
  •  Gokhale, N. Medical management approach to infectious keratitis. Indian J. Ophthalmol. 56, 215–220 (2008).
  •  Höfling-Lima, A. L., Bandeira, F. & Md, S. Management of acute bacterial keratitis: Fortified antibiotics or fluoroquinolones? Pan-Am 13, 70–72 (2014).
  •  Austin, A., Lietman, T. & Rose-Nussbaumer, J. Update on the Management of Infectious Keratitis. Ophthalmology vol. 124 1678–1689 (2017).
  •  Jung, H. J., Abou-Jaoude, M., Carbia, B. E., Plummer, C. & Chauhan, A. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. J. Control. Release 165, 82–89 (2013).
  • Lavik, E., Kuehn, M. H. & Kwon, Y. H. Novel drug delivery systems for glaucoma. Eye 25, 578–586 (2011).
  • Hiratani, H. & Alvarez-Lorenzo, C. The nature of backbone monomers determines the performance of imprinted soft contact lenses as timolol drug delivery systems. Biomaterials 25, 1105–1113 (2004).
  •  Venkatesh, S., Sizemore, S., Tamiya, Y., Mizutani, Y. & Alvarev-Lorenzo, C. Novel biomimetic hydrogels for enhanced loading and extended release of ocular therapeutics. Biomaterials 26, 1293–1298 (2005).
  •  Hiratani, H., Fujiwara, A., Tamiya, Y., Mizutani, Y. & Alvarez-Lorenzo, C. Ocular release of timolol from molecularly imprinted soft contact lenses. Biomaterials 26, 1293–1298 (2005).
  • 41. Jung, H. J. & Chauhan, A. Temperature sensitive contact lenses for triggered ophthalmic drug delivery. Biomaterials 33, 2289–2300 (2012).
  • .
  • Gulsen, D. & Chauhan, A. Ophthalmic drug delivery through contact lenses. Investig. Ophthalmol. Vis. Sci. 45, 2342–2347 (2004).
  • Kapoor, Y., Thomas, J. C., Tan, G., John, V. T. & Chauhan, A. Surfactant-laden soft contact lenses for extended delivery of ophthalmic drugs. Biomaterials 30, 867–878 (2009).
  • Ciolino, J. B. et al. A drug-eluting contact lens. Invest. Ophthalmol. Vis. Sci. 50, 3346–52 (2009).
  • Ciolino, J. B. et al. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys. Ophthalmology 123, 2085–2092 (2016).
  •  Lanier, O. L. et al. Commercialization challenges for drug eluting contact lenses. Expert Opin. Drug Deliv. (2020).
  • 47. Kim, J., Peng, C. C. & Chauhan, A. Extended release of dexamethasone from silicone-hydrogel contact lenses containing vitamin E. J. Control. Release 148, 110–116 (2010).
  •  Dixon, P. et al. Controlled delivery of pirfenidone through vitamin E-loaded contact lens ameliorates corneal inflammation. Drug Deliv. Transl. Res. 8, 1114–1126 (2018).
  • Hsu, K.-H., Carbia, B. E., Plummer, C. & Chauhan, A. Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy. Eur. J. Pharm. Biopharm. 94, 312–321 (2015).
  •  Giblin, F. J. Glutathione: A vital lens antioxidant. J. Ocul. Pharmacol. Ther. 16, 121–135 (2000).
  •  Winkler, B. S., Boulton, M. E., Gottsch, J. D. & Sternberg, P. Oxidative damage and age-related macular degeneration. Mol. Vis. 5, 32 (1999).
  •  Cai, J., Nelson, K. C., Wu, M., Sternberg, P. & Jones, D. P. Oxidative damage and protection of the RPE. Prog. Retin. Eye Res. 19, 205–221 (2000).
  •  Agardh, E., Hultberg, B. & Agardh, C. D. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. Curr. Eye Res. 21, 543–549 (2000).
  •  Bilgihan, K., Adiguzel, U., Sezer, C., Akyol, G. & Hasanreisoglu, B. Effects of topical vitamin E on keratocyte apoptosis after traditional photorefractive keratectomy. Ophthalmologica 215, 192–196 (2001).
  •  Nagata, M., Kojima, M. & Sasaki, K. Effect of vitamin E eye drops on naphthalene-induced cataract in rats. J. Ocul. Pharmacol. Ther. 15, 345–350 (1999).
  •  Ohta, Y., Yamasaki, T., Niwa, T., Majima, Y. & Ishiguro, I. Preventive effect of topical vitamin E-containing liposome instillation on the progression of galactose cataract. Comparison between 5-week- and 12- week-old rats fed a 25% galactose diet. Exp. Eye Res. 68, 747–755 (1999).
  •  Seth, R. K. & Kharb, S. Protective function of alpha-tocopherol against the process of cataractogenesis in humans. Ann. Nutr. Metab. 43, 286–289 (1999).
  •  Yang, M. et al. Experimental studies on soft contact lenses for controlled ocular delivery of pirfinedone: in vitro and in vivo. Drug Deliv. 23, 3538–3543 (2016).